In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles
Mucoromycoses (infections caused by members of the order Mucorales, phylum Mucoromycota [ex-Zygomycota]) are highly destructive, rapidly progressive infections, with dire prognoses especially when they occur in immunocompromised hosts. Current treatment guidelines recommend liposomal formulations of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Journal of Fungi |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2309-608X/7/4/271 |
| _version_ | 1797539004972793856 |
|---|---|
| author | Andrew M. Borman Mark Fraser Zoe Patterson Michael D. Palmer Elizabeth M. Johnson |
| author_facet | Andrew M. Borman Mark Fraser Zoe Patterson Michael D. Palmer Elizabeth M. Johnson |
| author_sort | Andrew M. Borman |
| collection | DOAJ |
| description | Mucoromycoses (infections caused by members of the order Mucorales, phylum Mucoromycota [ex-Zygomycota]) are highly destructive, rapidly progressive infections, with dire prognoses especially when they occur in immunocompromised hosts. Current treatment guidelines recommend liposomal formulations of amphotericin B with adjunctive surgery as first line therapy, with the newer triazoles posaconazole or isavuconazole as alternative treatments, or as salvage therapy. Among the many organisms belonging to this order, a limited number of species in the genera <i>Rhizopus</i>, <i>Mucor</i>, <i>Lichtheimia</i> and <i>Rhizomucor</i> are responsible for most cases of human infection. Here, we present the minimum inhibitory concentration data (MICs) for amphotericin B, posaconazole, isavuconazole, itraconazole and voriconazole with a panel of over 300 isolates of the five most common agents of human infection (<i>Lichtheimia corymbifera</i>, <i>Rhizopus arrhizus</i>, <i>R. microsporus</i>, <i>Rhizomucor pusillus</i> and <i>Mucor</i> spp.) determined using the CLSI broth microdilution method. In agreement with previous studies, the most active antifungal drug for all Mucorales was amphotericin B, with MICs within the range that would predict susceptibility with <i>Aspergillus fumigatus</i>. Conversely, MICs for voriconazole against all species tested were high, and above the range associated with clinical efficacy with <i>A. fumigatus</i>. Interestingly, whilst isavuconazole and posaconazole MIC distributions indicated in vitro activity against some members of the Mucorales, activity was species-dependent for both agents. These data underscore the importance of accurate identification of the causative agents of mucoromycosis, coupled with antifungal susceptibility testing of individual isolates, in determining the optimal treatment of infections caused by these aggressive opportunistic human fungal pathogens. |
| first_indexed | 2024-03-10T12:39:14Z |
| format | Article |
| id | doaj.art-02f452a087b74d92a499eb24edadefb8 |
| institution | Directory Open Access Journal |
| issn | 2309-608X |
| language | English |
| last_indexed | 2024-03-10T12:39:14Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Fungi |
| spelling | doaj.art-02f452a087b74d92a499eb24edadefb82023-11-21T13:58:13ZengMDPI AGJournal of Fungi2309-608X2021-04-017427110.3390/jof7040271In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer TriazolesAndrew M. Borman0Mark Fraser1Zoe Patterson2Michael D. Palmer3Elizabeth M. Johnson4UK National Mycology Reference Laboratory, Public Health England, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UKUK National Mycology Reference Laboratory, Public Health England, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UKUK National Mycology Reference Laboratory, Public Health England, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UKUK National Mycology Reference Laboratory, Public Health England, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UKUK National Mycology Reference Laboratory, Public Health England, Science Quarter, Southmead Hospital, Bristol BS10 5NB, UKMucoromycoses (infections caused by members of the order Mucorales, phylum Mucoromycota [ex-Zygomycota]) are highly destructive, rapidly progressive infections, with dire prognoses especially when they occur in immunocompromised hosts. Current treatment guidelines recommend liposomal formulations of amphotericin B with adjunctive surgery as first line therapy, with the newer triazoles posaconazole or isavuconazole as alternative treatments, or as salvage therapy. Among the many organisms belonging to this order, a limited number of species in the genera <i>Rhizopus</i>, <i>Mucor</i>, <i>Lichtheimia</i> and <i>Rhizomucor</i> are responsible for most cases of human infection. Here, we present the minimum inhibitory concentration data (MICs) for amphotericin B, posaconazole, isavuconazole, itraconazole and voriconazole with a panel of over 300 isolates of the five most common agents of human infection (<i>Lichtheimia corymbifera</i>, <i>Rhizopus arrhizus</i>, <i>R. microsporus</i>, <i>Rhizomucor pusillus</i> and <i>Mucor</i> spp.) determined using the CLSI broth microdilution method. In agreement with previous studies, the most active antifungal drug for all Mucorales was amphotericin B, with MICs within the range that would predict susceptibility with <i>Aspergillus fumigatus</i>. Conversely, MICs for voriconazole against all species tested were high, and above the range associated with clinical efficacy with <i>A. fumigatus</i>. Interestingly, whilst isavuconazole and posaconazole MIC distributions indicated in vitro activity against some members of the Mucorales, activity was species-dependent for both agents. These data underscore the importance of accurate identification of the causative agents of mucoromycosis, coupled with antifungal susceptibility testing of individual isolates, in determining the optimal treatment of infections caused by these aggressive opportunistic human fungal pathogens.https://www.mdpi.com/2309-608X/7/4/271MucoromycotaMucoralesantifungal susceptibility testingminimum inhibitory concentrationsamphotericin Bposaconazole |
| spellingShingle | Andrew M. Borman Mark Fraser Zoe Patterson Michael D. Palmer Elizabeth M. Johnson In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles Journal of Fungi Mucoromycota Mucorales antifungal susceptibility testing minimum inhibitory concentrations amphotericin B posaconazole |
| title | In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles |
| title_full | In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles |
| title_fullStr | In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles |
| title_full_unstemmed | In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles |
| title_short | In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles |
| title_sort | in vitro antifungal drug resistance profiles of clinically relevant members of the mucorales mucoromycota especially with the newer triazoles |
| topic | Mucoromycota Mucorales antifungal susceptibility testing minimum inhibitory concentrations amphotericin B posaconazole |
| url | https://www.mdpi.com/2309-608X/7/4/271 |
| work_keys_str_mv | AT andrewmborman invitroantifungaldrugresistanceprofilesofclinicallyrelevantmembersofthemucoralesmucoromycotaespeciallywiththenewertriazoles AT markfraser invitroantifungaldrugresistanceprofilesofclinicallyrelevantmembersofthemucoralesmucoromycotaespeciallywiththenewertriazoles AT zoepatterson invitroantifungaldrugresistanceprofilesofclinicallyrelevantmembersofthemucoralesmucoromycotaespeciallywiththenewertriazoles AT michaeldpalmer invitroantifungaldrugresistanceprofilesofclinicallyrelevantmembersofthemucoralesmucoromycotaespeciallywiththenewertriazoles AT elizabethmjohnson invitroantifungaldrugresistanceprofilesofclinicallyrelevantmembersofthemucoralesmucoromycotaespeciallywiththenewertriazoles |